Companion Diagnostics ( CDx ) Market size is expected to reach US $ 5.0 Billion by 2024 , growing at a CAGR of 12.0 % from 2016 to 2024
The global companion diagnostics ( CDx ) market was valued at US $ 1,614.5 million in 2015 and is projected to expand at a CAGR of 12.0 % during the forecast period 2016 to 2024
Companion diagnostic ( CDx ) is a diagnostic tool used to determine the suitability of a drug therapy to the patient . It has become a critical part of targeted cancer therapy that allows for development of personalized therapy can be developed and administered to the patient . Whole blood samples , tissues samples , or buccal samples are collected and tested for diagnosis and identification of targeted disease biomarker . CDx is usually utilized in identifying genetic mutations and the health and treatment approach implications . In July 2016 , the U . S . FDA released a draft guideline for development of a therapeutic product accompanying an IVD companion diagnostic . Companion diagnostics include Gleevec ( imatinib